
AGN 193109
CAS No. 171746-21-7
AGN 193109( —— )
Catalog No. M22422 CAS No. 171746-21-7
AGN 193109, a retinoid analog, is a potent and specific antagonist of RARs (Kds: 2 nM, 2 nM, and 3 nM for RARα, RARβ, and RARγ).AGN 193109 is completely RAR specific because it does not bind to or transactivate through any of the RXRs.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
2MG | 83 | In Stock |
![]() ![]() |
5MG | 140 | In Stock |
![]() ![]() |
10MG | 222 | In Stock |
![]() ![]() |
25MG | 448 | In Stock |
![]() ![]() |
50MG | 653 | In Stock |
![]() ![]() |
100MG | 888 | In Stock |
![]() ![]() |
200MG | Get Quote | In Stock |
![]() ![]() |
500MG | Get Quote | In Stock |
![]() ![]() |
1G | Get Quote | In Stock |
![]() ![]() |
Biological Information
-
Product NameAGN 193109
-
NoteResearch use only, not for human use.
-
Brief DescriptionAGN 193109, a retinoid analog, is a potent and specific antagonist of RARs (Kds: 2 nM, 2 nM, and 3 nM for RARα, RARβ, and RARγ).AGN 193109 is completely RAR specific because it does not bind to or transactivate through any of the RXRs.
-
DescriptionAGN 193109, a retinoid analog, is a potent and specific antagonist of RARs (Kds: 2 nM, 2 nM, and 3 nM for RARα, RARβ, and RARγ).AGN 193109 is completely RAR specific because it does not bind to or transactivate through any of the RXRs . AGN 193109 (100 nM) inhibits the TTNPB (a retinoic acid receptor agonist)-dependent morphological change in ECE16-1 cells. AGN193109 half-reverses retinoid-dependent growth suppression at 10 nM, and completely shows this effect at 100 nM in ECE16-1 cells. AGN193109 (100 nM) also eliminates TTNPB-induced decrease in levels of K5, K6, K14, K16, and K17 and increases in levels of K7, K8, and K19 .AGN 193109 (0.30 or 1.20 μmol/kg) by topical treatment significantly reduces both weight loss and cutaneous toxicity caused by oral TTNPB cotreatment. AGN 193109 (1.15 μmol/kg) does not cause overt toxicity and has no effect on spleen weight on the mice, but it suppresses TTNPB-induced increase in spleen weight of the mice. AGN 193109 also significantly reduces the cutaneous toxicity induced by ATRA.(In Vitro):AGN 193109 (0.1 and 1 μmol/L; 3 w) dose-dependently increases vascular smooth muscle cells (VSMCs) mineralization.AGN 193109 (100?nM; 10 d) induces human pluripotent stem cells (hPSCs) differentiate into olfactory placode cells and neurons.
-
In VitroAGN 193109 (0.1 and 1 μmol/L; 3 w) dose-dependently increases vascular smooth muscle cells (VSMCs) mineralization.AGN 193109 (100?nM; 10 d) induces human pluripotent stem cells (hPSCs) differentiate into olfactory placode cells and neurons.
-
In Vivo——
-
Synonyms——
-
PathwayMetabolic Enzyme/Protease
-
TargetRetinoid Receptor
-
RecptorRARα| RARβ| RARγ
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number171746-21-7
-
Formula Weight392.49
-
Molecular FormulaC28H24O2
-
Purity>98% (HPLC)
-
SolubilityDMSO:2 mg/mL (5.10 mM; Need warming)
-
SMILESCc1ccc(cc1)C1=CCC(C)(C)c2ccc(cc12)C#Cc1ccc(cc1)C(O)=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Johnson AT, et al. Synthesis and characterization of a highly potent and effective antagonist of retinoic acid receptors. J Med Chem. 1995 Nov 24;38(24):4764-7.
molnova catalog



related products
-
BMS 753
BMS 753 is an agonist of isotype-selective retinoic acid receptor α (RARα, Ki= 2 nM).
-
Acitretin
Acitretin(Ro 10-1670) is a second-generation, systemic retinoid that has been used in the treatment of psoriasis.
-
Quisinostat 2HCl
Quisinostat (JNJ-26481585) 2HCl is a novel second-generation HDAC inhibitor with highest potency for HDAC1 with IC50 of 0.11 nM in a cell-free assay.